Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
LEADER: Liraglutide Cardiovascular Outcomes in Type 2 Diabetes
NCT01179048Phase 3Completed
- Sponsor
- Novo Nordisk
- Start
- Aug 2010
- Primary completion
- Dec 2015
- Modality
- Peptides
- Countries
- 33
01
Overview
Phase 3, randomised, double-blind trial in type 2 diabetes mellitus (T2DM) comparing Liraglutide with Placebo (2 arms). Primary endpoint: Time From Randomisation to First Occurrence of Cardiovascular Death, Non-fatal Myocardial Infarction, or Non-fatal Stroke up to 60 months. Started Aug 2010; status: completed.
02
Drugs
03
Conditions
type 2 diabetes mellitus (T2DM)
Beyond the preview
Go deeper on NCT01179048.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01179048.